XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Acquisition and Equity-Method Investment - Acquisitions Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 6 Months Ended
Dec. 14, 2023
Jul. 02, 2023
Jun. 30, 2024
Jul. 02, 2023
Business Acquisition [Line Items]        
Acquisitions of businesses, net of cash acquired     $ 0 $ 25
Seagen [Member]        
Business Acquisition [Line Items]        
Business acquisition, per share in cash (in dollars per share) $ 229      
Payments to acquire business, gross $ 44,200      
Acquisitions of businesses, net of cash acquired $ 43,400      
Pro Forma net loss attributable to Pfizer Inc. common shareholders   $ (1,389)   (6,040)
Seagen [Member] | Amortization Expense [Member]        
Business Acquisition [Line Items]        
Pro Forma net loss attributable to Pfizer Inc. common shareholders   143   285
Seagen [Member] | Fair Value Adjustment to Inventory [Member]        
Business Acquisition [Line Items]        
Pro Forma net loss attributable to Pfizer Inc. common shareholders   224   449
Seagen [Member] | Interest Expense [Member]        
Business Acquisition [Line Items]        
Pro Forma net loss attributable to Pfizer Inc. common shareholders   303   791
Seagen [Member] | Interest Income [Member]        
Business Acquisition [Line Items]        
Pro Forma net loss attributable to Pfizer Inc. common shareholders   $ 263   $ 330